A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome

NCT01427816 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2013-10-30

No results posted yet for this study

Summary

To evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndrome.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

KCT-0809

DRUG

KCT-0809

DRUG

Placebo

Sponsors & Collaborators

  • Kissei Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Katsumi Hontani · Clinical Development Department, Kissei pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01427816 on ClinicalTrials.gov